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Abstract
Cohesin regulates sister chromatid cohesion during the mitotic cell cycle with Nipped-B-Like (NIPBL) facilitating its loading
and unloading. In addition to this canonical role, cohesin has also been demonstrated to play a critical role in regulation of
gene expression in nondividing cells. Heterozygous mutations in the cohesin regulator NIPBL or cohesin structural
components SMC1A and SMC3 result in the multisystem developmental disorder Cornelia de Lange Syndrome (CdLS).
Genome-wide assessment of transcription in 16 mutant cell lines from severely affected CdLS probands has identified a
unique profile of dysregulated gene expression that was validated in an additional 101 samples and correlates with
phenotypic severity. This profile could serve as a diagnostic and classification tool. Cohesin binding analysis demonstrates a
preference for intergenic regions suggesting a cis-regulatory function mimicking that of a boundary/insulator interacting
protein. However, the binding sites are enriched within the promoter regions of the dysregulated genes and are
significantly decreased in CdLS proband, indicating an alternative role of cohesin as a transcription factor.
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Introduction
Cohesin is an evolutionally conserved multisubunit protein
complex consisting of an SMC1A and SMC3 heterodimer, and at
least two non-SMC proteins SCC1 (also known as RAD21 or
MCD1) and SCC3 (also known as SA or STAG). Cohesin controls
sister chromatid cohesion during S phase with Nipped-B-Like
(NIPBL) facilitating its loading and unloading [1]. ESCO2
possesses acetyltransferase activity and is involved in the
establishment of cohesion [2]. Cohesin is loaded onto chromatin
during G1/S phase in budding yeast and during telophase of the
preceding cell division in vertebrates. Loading of cohesin also
happens during G2/M phase when double strand DNA breaks are
generated [3]. Removal of cohesin from chromosome arms begins
during prophase and completes by separase-mediated dissolving of
the remaining cohesin from centromeres during anaphase [3].
Although no consensus DNA sequence for cohesin binding has
been demonstrated, cohesin is enriched at heterochromatin [4]
and DNA double-strand breaks (DSBs) [5]. A large amount of
intact and free cohesin is associated with chromosomes for most of
the cell division cycle because of a separase independent
mechanism [6–8]. A noncanonical role for cohesin as a key
regulator of gene expression has been proposed [9]. The Drosophila
NIPBL homolog, Nipped-B, alleviates the gypsy insulator function
by assisting in long distance enhancer–promoter interactions to
activate cut and Ultrabithorax expression. Nipped-B and cohesin
colocalize and bind preferentially to active transcription units [9].
Recently, CTCF was reported to colocalize with cohesin and
required for cohesin binding to chromatin [10,11]. CTCF is the
only protein known to bind to all vertebrate chromatin insulators
and was initially identified as a transcription factor that binds to
mammalian c-MYC promoters [12]. In addition, CTCF is well
studied for its role in regulating genomic imprinting, and is
proposed to regulate higher order chromatin structures such as
intra- and interchromosomal association [13,14]. CTCF is
required for Tsix transactivation and involved in maintaining
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sequences in several genetic disorders, and has been suggested to
act as a tumor suppressor gene [15]. CTCF binding sites have
been mapped in the human genome [16].
Cornelia de Lange syndrome (CdLS, Online Mendelian
Inheritance in Man [OMIM] 122470, 300590, and 610759) is a
dominant disorder with multisystem abnormalities including
characteristic facial features, hirsutism, upper extremity defects,
gastroesophageal dysfunction, growth, and neurodevelopmental
delays. The incidence is about one in 10,000, with most cases being
sporadic. There is equal gender distribution with a high degree of
phenotypic variability. About 60% of the probands with CdLS have
heterozygous mutations in the NIPBL gene, whereas 5% have
mutations in the SMC1A gene, and one patient was found to have a
mutation in the SMC3 gene [17,18]. Other multisystem develop-
mental disorders have been found to be caused by mutations in
cohesin-related genes, such as Roberts-SC phocomelia (RBS,
OMIM 268300) an autosomal recessive disorder caused by either
homozygous or compound heterozygous mutations in the ESCO2
gene [19]. These disorders have collectively been termed ‘‘cohesi-
nopathies.’’ Given the paucity of sister chromatid cohesion defects
observed in individuals with CdLS [20], we hypothesize that it is the
newly established role of cohesin in gene regulation that results in
the multisystem phenotype when disrupted. To study the effects of
disruption of cohesin on gene expression in human cells we have
utilized lymphoblastoid cell lines (LCLs) from individuals with
CdLS that harbor known heterozygous mutations in the cohesin
regulator NIPBL and cohesin structural component SMC1A and
applied a genome-wide approach to analyze gene transcription and
cohesin binding.
Results
Specific Genes Are Differentially Expressed in CdLS
Probands with NIPBL Mutations
LCLs from 16 severely affected CdLS probands with NIPBL
protein-truncating mutations as well as 17 age, gender, and race
matched healthy controls were used as training samples for assays
on the Affymetrix HG-U133 plus 2.0 expression arrays, six
additional individuals including one CdLS proband, one healthy
control, two RBS probands (a related cohesinopathy), and two
Alagille syndrome (AGS) probands (an unrelated multisystem
dominant developmental disorder caused by disruption in the
Notch signaling pathway) served as testing samples (Table S1A
and S1B). 27,995 probe sets (12,740 nonredundant genes) were
considered to be expressed in human LCLs. Unsupervised sample
clustering by principle component analysis (PCA) of all the
expressed probe sets was able to separate probands from controls
in the training set indicating these two groups have different gene
expression patterns (Figure 1A). Differential expression of these
27,995 probe sets was ranked by F=(between group variance)/
(within group variance). Permutation analysis was performed 100
times and false discovery rate (FDR) was calculated for each F
score, whereas redundancy was collapsed by keeping the ones with
the highest F scores. We have identified a group of 1,915 probe
sets (1,501 nonredundant genes) with FDR,0.05 and 420 probe
sets (339 nonredundant genes) with FDR,0.01 (Tables S2 and S3)
that are differentially expressed in CdLS. Heatmap representation
of the expression levels of these genes clearly demonstrates that the
expression of the 420 probe sets is remarkably different between
CdLS probands and controls (Figure 1B). NIPBL itself had the
highest ranking, with FDR=0 and a fold change of 21.34.
In order to examine whether CdLS probands could be
differentiated from controls through expression profiling, Leave-
One-Out cross validation was performed on the training set. The
top 400 probe sets were selected on each of the 33 rounds that
corresponded to an FDR<0.01. The left-out samples were
successfully classified into two distinct groups using nearest
centroid method with the exception of two controls and one
proband that were misclassified (Figure 1C). The area under the
receiver operating characteristic (ROC) curve is 0.985 with test
accuracy of 91% (95% confidence interval=76%–98%). Nearest
centroid classification method was further performed on the six
testing samples based on the identified 420 probe sets
(FDR,0.01). The one healthy control and two individuals with
AGS were classified as controls; one CdLS and two RBS probands
were classified as probands (Figure 1C and Table S4). RBS is due
to the mutations in the ESCO2 gene that also regulates cohesin,
whereas AGS is an independent genetic disorder due primarily to
mutations in the JAG1 gene, a member of the Notch signaling
pathway. Thus, although limited to only two samples, it appears
that RBS shares a similar transcription profile with CdLS,
consistent with these two disorders being caused by disruption of
the cohesin pathway. It is of interest that whereas the two RBS
probands were classified as CdLS, their discriminant scores (DS)
were actually midway between the scores of CdLS probands and
the controls suggesting RBS might have an intermediate
transcription profile to CdLS and controls (Figure 1C).
Specific Gene Expression Is Tightly Associated with
Phenotypic Severity among Different Groups of CdLS
Probands
Clustering-based feature selection was carried out on the 339
nonredundant genes (420 probe sets, FDR,0.01) to identify
independent pathways or functional groups. Five clusters were
discovered (Table S5) and 32 genes (Table S6) were chosen for
further custom array validation according to smaller FDR, bigger
fold change, and less redundancy.
A cohort of 101 samples including individuals with different
phenotypes (healthy, CdLS, or other disorders) and various gene
mutations (Table S7) were measured on custom arrays carrying 56
Author Summary
Appropriate segregation of chromosomes to daughter
cells depends upon proper cohesion of sister chromatids
during mitosis. The multiprotein cohesin complex and its
regulators are key factors in this process. Intriguingly,
recent work has shown that the cohesin complex also has
other cellular roles, including a role in regulating gene
expression. Additionally, mutations in cohesin structural
and regulatory components have been linked to human
multisystem developmental disorders such as Cornelia de
Lange Syndrome (CdLS), but the role cohesin is playing in
the pathogenesis of this disorder is unknown. To define
the role that cohesin plays in regulating gene expression in
human cells, we analyzed gene expression and genome-
wide cohesin binding patterns in cells from normal
subjects and from CdLS probands with mutations in the
cohesin regulator NIPBL or in the cohesin structural
component SMC1A. We found a strikingly conserved
pattern of gene dysregulation in these different cell lines
that correlates with disease severity and a significant
correlation between gene dysregulation and cohesin
binding around misexpressed genes. The observed pattern
of binding and misexpression is consistent with cohesin
having a putative role as a boundary/insulator interacting
protein or transcription factor, the activity of which is
disrupted in CdLS probands.
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PLoS Biology | www.plosbiology.org 2 May 2009 | Volume 7 | Issue 5 | e1000119Figure 1. Classifications of the 33 training samples by gene expression. (A) Unsupervised clustering of 17 healthy controls (blue dots) and
16 severe CdLS probands (red dots) by principle component analysis (PCA) of the 27,995 probe sets actively transcribed in LCLs. The separation
between the training groups indicates that controls and probands have different gene expression patterns. (B) Heatmap showing that the identified
420 probe sets (FDR,0.01) are expressed dramatically differently between CdLS probands (PT) and healthy controls (N). Red represents genes that
are upregulated and blue represents genes that are downregulated. The left 17 columns represent control samples, and the right 16 columns
represent proband samples. Rows display gene expression levels. (C) Nearest centroid classifications of the 33 training samples and six testing
samples. Among the training samples, two healthy controls and one CdLS proband were misclassified after Leave-One-Out cross validation. Among
the testing samples, CdLS probands and two RBS probands were classified into CdLS group whereas the one healthy control and two probands with
AGS were classified into the control group.
doi:10.1371/journal.pbio.1000119.g001
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have followed a step-wise procedure to identify classifiers
according to different CdLS subgroups, and applied nearest
centroid classifications on all 101 samples (Table S9A and S9B).
Detailed analysis is described in Text S1. A 23-gene classifier can
be used to categorize CdLS probands with NIPBL mutations from
the rest of the samples including non-CdLS, CdLS probands with
SMC1A mutations, and CdLS probands without an identifiable
gene mutation. This indicates that the expression of these 23 genes
is tightly correlated to NIPBL function. To improve the generality
of the classifier, we randomly selected 15 mild probands with
NIPBL mutations as a new training group. Expression of ten of the
23 genes was significantly different between this group and the
original 17 controls and was also capable of subclassifying all
CdLS probands from non-CdLS controls, regardless of the gene
mutations or clinical presentations of the probands. This suggests
that expression of these ten genes is affected by a CdLS specific
disease process. For both classifications, the expression levels of the
classifier genes are tightly correlated to disease severity. A clear
progression of increasing discriminant scores (DS) can be seen
from healthy controls through mild, moderate, and severe CdLS
probands (Figure 2A and 2B). In addition, we have identified three
genes NFATC2, PAPSS2, and ZNF608 that could be used as
biomarkers for CdLS (Figure S1A and S1B). The phenotype
associated gene expression profiles strongly suggest either direct or
indirect roles for the identified genes.
Cohesin Binding Is Involved in Gene Expression in
Human Cells
Cohesin is a multisubunit complex constructed from SMC1A,
SMC3, RAD21, and SCC3 subunits. Mutations in SMC1A or
SMC3 and the cohesin regulator NIPBL lead to the human
developmental disorder CdLS. To test the hypothesis that cohesin
regulates transcription through its chromatin binding activity and
that this association is regulated by NIPBL activity we undertook
whole genome mapping of cohesin binding sites in LCLs from two
healthy controls and one severely affected CdLS proband with an
NIPBL mutation. Because of our inability to identify an effective
antibody with high specificity against NIPBL or SMC1A, we chose
an antibody against RAD21 (one of the other key components of
the cohesin complex) to map genome-wide cohesin binding sites.
Chromatin immunoprecipitation (ChIP) using a polyclonal
antibody against human RAD21 was performed and products
were hybridized on Affymatrix 2.0 tiling arrays. The score of
model-based analysis of tiling-arrays algorithm (MAT) was
calculated and probes were mapped to genomic positions. Peaks
representing genomic regions bound by hRAD21 were identified
with a p,10
26 and FDR,0.01.
The 54,675 probe sets on Affymetrix HG-U133 plus 2.0
expression array can be unambiguously mapped to 15,162 unique
RefSeq mRNAs including 10,378 transcribed and 4,784 nontran-
scribed genes in LCLs. 78% of the 15,162 mapped genes do not
harbor intragenic cohesin sites (Here, ‘‘intragenic’’ means genomic
region from the transcription start site [TSS] of a gene to the
transcription termination site [TTS] of the same gene), and
cohesin binds at variable distances outside those genes. 22% of the
15,162 mapped genes harbor intragenic cohesin sites, this number
is reduced to 19.0% in the silent nontranscribed genes (p#7.2e26)
and no change in the disease neutral genes (22.9%, p#0.0864); on
the contrary, more of the differentially expressed genes harbor
cohesin sites (27.0%, p#7.44e25) (http://145.18.230.98/Service/
Statistics/Binomial_proportions.html) (Table S10) suggesting a
correlation between intragenic cohesin binding and gene expres-
sion. For the 22% of genes with intragenic cohesin sites, cohesin
preferentially binds to a narrowed region surrounding the TSSs or
the TTSs with frequency at the TTSs only half of that at the TSSs.
The 100-kb regions spanning upstream and downstream of the
genes have only background levels of cohesin binding (Figure 3A
and 3B). Among controls, the degree of cohesin binding within +/
2 1 kb of the TSSs is greatest for those genes that are actively
transcribed and especially in those genes that are differentially
expressed in the NIPBL mutant cell lines, whereas the silent
nontranscribed genes have the same, or lower level, of enrichment
as the background level (Figure 4A). In addition, cohesin binding is
enriched at the 59-UTRs only for actively transcribed genes, with
no binding difference at exons, introns, or 39-UTRs between the
actively transcribed and silent genes (Figure 4B). Identification of
overrepresented cohesin binding near promoters suggests that
cohesin may regulate gene expression as a transcription factor. In
spite of this, the majority of the expressed genes (78%) do not
harbor any cohesin binding sites in their intragenic regions,
indicating most of the genes in the human genome may be
regulated by cohesin independent pathways or cohesin is involved
in their expression regulation through an alterative mechanism.
We further evaluated 13 genomic loci based on their gene
expression alterations to validate their cohesin binding status by
the more sensitive method of ChIP-quantitative PCR (qPCR). Out
of these 13 loci, two regions are equally bound by cohesin in both
healthy and CdLS cells, two regions are not bound by cohesin in
either healthy or CdLS cells, and the remaining nine loci
demonstrated significant loss of cohesin binding in CdLS cells as
compared to control cells. The ChIP-qPCR results are consistent
with cohesin binding alterations detected by ChIP array studies
(Figure S2A and S2B, Table S11).
Reduced Cohesin Binding Correlates with Transcription
Dysregulation in CdLS
The total number of cohesin binding sites is reduced by 29.7%
(9,530 versus 13,560) in the examined CdLS proband, but the
total number of binding sites at TSSs is reduced by 43.4% (448
versus 792) in the same proband, suggesting that cohesin is more
likely to be removed from TSSs (43.4% versus 29.7%, p=5.9e28)
(Table 1). The 10,378 genes expressed in LCLs have been
statistically ranked for their misexpression in CdLS probands as
described above. In the controls, there exist 666 LCL expressed
genes that have cohesin binding sites mapped to the +/2 1-kb
vicinity of TSSs, and 107 of them are identified as differentially
expressed in CdLS (FDR,0.05). In CdLS, only 376 such genes
have cohesin sites around their TSSs (376 versus 666, reduced by
43.5%), only 53 of the 107 differentially expressed genes still
maintain their TSS/cohesin association, whereas the rest have all
lost their TSS cohesin binding sites (53 versus 107, reduced by
50.5%) in the proband (Table 2). At the TSSs, the number of
cohesin sites on differentially expressed genes is significantly
reduced in CdLS, whereas the reduction is moderate for the
nondifferentially expressed genes, and only minimal for those
silent nontranscribed genes (Figure 4A). The binding between
cohesin and TSSs of expressed genes is highly correlated to the
CdLS phenotype. In our identified panel of differentially expressed
genes in CdLS, Fisher testing on the ChIP data shows that these
genes tend to attract more cohesin to their TSSs in control cells
under the healthy condition (p=10e24) than the neutral genes do,
whereas under the diseased condition in CdLS cells, those genes
tend to lose their capability to recruit cohesin and associate with
cohesin at a similar level to the neutral genes and have lost their
statistically significant difference (p=0.1) (Table 2). This 2-kb
region (+/2 1 kb surrounding the TSS) was further analyzed for
the entire group of 10,378 genes expressed in LCLs that have been
NIPBL, Cohesin, and Transcription Regulation
PLoS Biology | www.plosbiology.org 4 May 2009 | Volume 7 | Issue 5 | e1000119Figure 2. Classifier genes are identified for CdLS. Clear progression of discriminant score (DS) from low to high is correlated with
the phenotype from unaffected R mild R moderate R severely affected with CdLS. (A) The 23-gene classifier separates CdLS probands
with NIPBL mutations from the rest of the individuals. Healthy controls, probands with other genetic disorders, CdLS probands with SMC1A mutations,
and CdLS probands with no gene mutation identified are distinctly separated from each other in a progressive manner correlated with phenotypic
severity. (B) The ten-gene classifier differentially categorizes all CdLS probands from non-CdLS individuals and plots correlate to the severity of the
CdLS probands. Healthy controls are labeled as ‘‘Control,’’ disease severity is described as ‘‘Mild,’’ ‘‘Moderate,’’ and ‘‘Severe’’ CdLS probands with NIPBL
mutations, SMC1A mutations or no identified gene mutation are labeled as ‘‘NIPBL,’’ ‘‘SMC1A,’’ or ‘‘No,’’ respectively. *, training samples; **, number of
mild cases with an NIPBL mutation was reduced from 26 in (A) to 11 in (B) with the other 15 cases having been used as training samples.
doi:10.1371/journal.pbio.1000119.g002
NIPBL, Cohesin, and Transcription Regulation
PLoS Biology | www.plosbiology.org 5 May 2009 | Volume 7 | Issue 5 | e1000119ranked for their differential expression in CdLS probands as
described above. Cohesin enrichment was clearly identified in
control cells for the top ranked genes and a dramatic decrease in
binding is demonstrated in the CdLS cells, suggesting that the
genes that harbor more cohesin sites around the promoter regions
are more likely to be misexpressed in CdLS (Figure 4C).
Moreover, this difference was even more remarkable if we
narrowed the analyzed region to the +/2 100-bp central area
surrounding TSSs (Figure S3).
To summarize, in control LCLs cohesin preferentially binds to
transcribed genes at the TSSs as compared to the silent
nontranscribed genes. The binding sites are even more enriched
for the differentially expressed genes. In CdLS, cells tend to lose
cohesin binding globally, however the cohesin sites at TSSs are
more likely to be lost, most notably for the differentially expressed
genes where loss of cohesin binding at the TSSs results in a
binding frequency approaching the background level. The
preferential binding to promoter regions suggests cohesin may
play a role as a transcription factor.
Recently cohesin has been functionally linked to CTCF, an
insulator capable of blocking enhancers or preventing the spread
of epigenetic signals [15]. In our study, the ion transporter protein
ATP11A is significantly downregulated in CdLS (FDR=0.027),
although the fold change is small (21.24). ATP11A locates within
ENCODE region ENr132 on Chromosome 13 with four other
genes. Therefore, the ENCODE datasets obtained from GM6990,
a similar EBV-transformed human B cell line (http://genome.ucsc.
edu/, http://www.sanger.ac.uk/PostGenomics/encode/data-access.
shtml), were able to be adapted for our analysis [21]. There are six
CTCF and two cohesin binding sites in this area, both cohesin sites
overlap with CTCF sites. In controls, this area can be split into three
chromatin regions according to multiple histone modification makers
(Figure 5A and 5B) [22–24], and cohesin and CTCF colocalize at
the border. Region 1 harbors only one gene C13orf35, which is not
expressed in LCLs. Region 3 harbors three genes, MCF2L, F7,a n d
F10, which are all expressed comparably in LCLs from both controls
and probands. The ENCODE study has shown that chromatin-
silencing marker H3K27me3 is enriched in region 3, but open
chromatin markers H3K4 me1/me2/me3, H3K36me3, and
H3K79me3, and DNaseI sensitive sequences are underrepresented,
indicating chromatin in this region is condensed and transcription
repressed [22–24]. In region 2, on the other hand, H3K4 is highly
methylated, H3 tails are vastly acetylated, and multiple DNaseI
sensitive sites appeared; meanwhile, H3K27 methylation level is
quite low indicating region 2 is an active open chromatin domain.
ATP11A is the only gene located in region 2 and differentially
expressed in CdLS. Of note, the cohesin binding site between
regions 2 and 3 at Chromosome 13: 112,645,000–112,645,600 is lost
in CdLS (Figure 5A and 5B). ChIP-qPCR was then performed using
specific primers to amplify this binding locus in an expanded sample
set including three healthy controls and three CdLS probands
(Figure 5C). Two of the three probands, PT2 and PT12, have NIPBL
truncating mutations with severely affected clinical features and have
been included in the whole genome expression array studies as
described above; the third proband CDL-017 has a mutation in the
SMC1A gene and manifests a much milder phenotype (Tables S1
and S7). Cohesin binding site 1 (Chromosome 3: 79653256–
79653385), which was not lost in CdLS according to our qualitative
array analysis was therefore used as a positive binding control. By
quantitative PCR assays, the enrichment of cohesin bound to site 1
was not found to be changed between controls and the probands,
which is consistent with the array findings. However, cohesin
binding was dramatically reduced, within Chromosome 13:
112,645,000–112,645,600 among CdLS probands including the
individual with the SMC1A mutation (Figure 5C). Although cohesin
binding was not completely lost in CdLS by ChIP-qPCR, the result
is consistent with the missing binding peak seen in the qualitative
ChIP array analysis. Although this dataset is limited, it suggests that
cohesin possesses a function as an insulator/boundary protein, in
addition, functional NIPBL is required for this process. With
disruption in the NIPBL mutated or cohesin subunit SMC1A mutated
human cells, the silent chromatin signals from region 3 appear to be
able to cross the boundary and migrate into region 2 to inhibit
ATP11A transcription. Cohesin and CTCF may function coopera-
tively at this locus owing to their colocalization. In addition, both
CTCF binding sites remained intact in CdLS, which may explain
why the downregulation of ATP11A was not dramatic (21.24).
Figure 3. Cohesin binding analyzed in 15,162 unique tran-
scripts demonstrates preferential binding to TSSs and TTSs. (A)
The frequency of cohesin binding has a sharp peak around TSS and falls
to the background level upstream of this peak. (B) The frequency of
cohesin binding has another peak around TTS. The height of this peak is
about half that of the peak height seen at TSS. Similarly the regions
downstream of this peak have a cohesin binding frequency close to the
background level.
doi:10.1371/journal.pbio.1000119.g003
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Analyses
Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Inc.,
http://www.ingenuity.com) was used to analyze the identified
differentially expressed genes. Out of the 339 genes with
FDR,0.01, 150 genes are documented in cancer, neurological,
hematological, skeletal and muscular, and dermatological diseases;
150 genes are identified as major players in embryonic and tissue
development, hematological and immune system development and
functions; in addition, 153 genes have well established cellular and
molecular functions in cell death, cell proliferation, and cell cycle
regulation. We have further analyzed the biological functions and
canonical pathways mediated by the 23- and 10-gene classifiers
and the three biomarkers as validated by target array (Table S12).
Interestingly, more than 60% (15 out of 23) of the identifier genes
harbor intragenic cohesin binding sites, which is much higher than
the average genome level (22%). Moreover, some of these genes
have completely lost their cohesin association in CdLS (Table
S12). Both groups of classifier genes are tightly related to pathways
of cell death, cellular development, and tissue morphology. 12 out
of these 23 genes are involved in 47 known biological functions or
disease conditions. Five of these 12 genes are also part of the 10-
gene classifier, including two genes, NFATC2 and PAPSS2, which
are the identified biomarkers for CdLS. The 23-gene classifier
could differentiate CdLS probands with NIPBL mutations
suggesting the expression of these 23 genes are tightly controlled
by NIPBL; whereas the 10-gene classifier is less powerful and only
able to identify CdLS probands without the ability to differentiate
subgroups of probands with different gene mutations, suggesting
that these ten genes are related to terminal events during CdLS
Figure 4. Frequency of cohesin binding around the TSS as related to transcriptional status in LCLs. Group A (silver), nontranscribed
silent genes in LCLs (4,784 unique Refseq mRNAs); group B (yellow), genes without expression alterations between controls and CdLS probands
(9,199 unique RefSeq mRNAs); group C (red), genes differentially expressed in CdLS (FDR , 0.05) (1,179 unique RefSeq mRNAs). (A) Frequency of
cohesin binding at the TSS of group C genes is much lower in CdLS than in control. Group B genes have a moderate reduction, and group A genes
have little change. Overall cohesin binding around the TSS is greatest for those genes that are actively transcribed in LCLs and especially in those
genes that are misexpressed in CdLS. (B) Within the intragenic regions, 59-UTRs of the actively transcribed genes (groups B and C) have higher
cohesin binding frequency in control than other intragenic regions whereas group A genes have frequency close to the background level in all
regions. In CdLS, the frequency dropped in all three gene groups in CdLS and the difference between different gene groups and regions tends to
diminish. (C) Cohesin binding within 2 kb around TSS is enriched in differentially expressed genes. The 10,378 unique genes expressed in LCLs are
ranked by their F scores. The reference enrichment is the percentage of genes having cohesin binding within 2 kb (+/2 1 kb) around TSS. The relative
enrichment is calculated as the value of cohesin binding enrichment in top-ranked genes over the reference enrichment. The relative enrichment
point is calculated for the total number of genes prior to the point on the x-axis. The numbers on x-axis denote the statistical ranks. The curves are
smoothed by the LOWESS algorithm.
doi:10.1371/journal.pbio.1000119.g004
Table 2. Differentially expressed genes tend to lose their cohesin binding at TSSs in CdLS samples.
Binding Sites Present Yes/No/Total
Number of Differentially
Expressed Genes (FDR,0.05) Total
Yes No
61-kb Vicinity of TSSs in controls
(Fisher’st e s tp=0.0001, OR=1.54 [1.23–1.92])
Yes 107 559 666
No 1,072 8,640 9,712
Total 1,179 9,199 10,378
61-kb Vicinity of TSSs in CdLS
(Fisher’st e s tp=0.1, OR=1.29 [0.94–1.75])
Yes 53 323 376
No 1,126 8,876 10,002
Total 1,179 9,199 10,378
Cohesin preferentially binds to the TSSs among differentially expressed genes in healthy controls, p=0.0001. Differentially expressed genes lose cohesin binding at their
TSSs in CdLS. The frequency is reduced to the same level as the genes without differential expression, p=0.1.
doi:10.1371/journal.pbio.1000119.t002
Table 1. Cohesin associated to the +/2 1-kb vicinities of TSSs among three different groups of genes in control and CdLS LCLs.
Group Expression Status in LCLs
Genes with Binding Sites Present at61-kb Region
Surrounding TSS
Control Cells
CdLS Cells
(FDR,0.05)
Unique RefSeq Genes
(15,162 in Total)
Control Cells
(792 in Total)
CdLS Cells
(448 in Total)
A No No 4,784 126 72
B Yes No (FDR.0.05) 9,199 559 323
C Yes Yes (FDR,0.05) 1,179 107 53
Group A is not transcribed in LCLs, groups B and C are transcribed in LCLs, whereas group C is differentially expressed in CdLS (FDR,0.05).
doi:10.1371/journal.pbio.1000119.t001
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NFATC2, MAP3K5, LTB, and PHF16, which are involved in
multiple reported events by IPA and are shared by the two
classifiers, might be involved in cellular functions that are
universally affected in CdLS. Presumably mutations in NIPBL,
SMC1A,o rSMC3, or as of yet unidentified CdLS causing gene
mutations, will all result in alterations of the related biological
functions controlled by these five genes. On the other hand, the
seven unique genes with functional roles that were excluded from
the 10-gene classifier, KIFAP3, AIM1, BBS9 (PTHB1), TSPAN12,
TRERF, ARHGAP24, and ID3, probably represent cellular
functions affected more specifically by NIPBL mutations. Four
genes, PAPSS2, NFATC2, MAP3K5, ADCY1, were identified to be
involved in 32 canonical pathways by IPA; they also regulate
multiple biological functions as mentioned above. ADCY1 is the
single gene out of the above four genes that exists in the 23-gene
classifier but is excluded from the 10-gene classifier; thus the
specific canonical pathways regulated by ADCY1 (i.e. B cell
receptor signaling, RAR activation, sulfur metabolism, and
endoplasmic reticulum stress pathways), could largely depend on
normal functions of NIPBL. Two out of the three biomarkers,
NFATC2 and PAPSS2, are reported to be involved in multiple
biological functions and canonical pathways by IPA analysis. The
third biomarker ZNF608 is a novel protein with very minimal
known functions. However, the zinc finger protein family
members are known to be the major players in many molecular
and cellular pathways.
One of the biomarkers, NFATC2, is involved in multiple
signaling pathways during development and affecting skeletal
myogenesis, chondrogenesis, axon growth, and guidance [25,26].
Two NFATC negative regulators both locate to the Down
syndrome critical region of human Chromosome 21, Nfatc2
2/2
and Nfatc4
2/2 double-knockout mice have physical and cognitive
features resembling human Down syndrome [27]. Dysregulation
of NFATC2 in the postnatal nervous system may contribute to
mental deficiency in CdLS. Another biomarker, PAPSS2, plays a
pivotal role in the biosynthesis of sulfate donors for sulfotransferase
reactions. Its activity is important for normal skeletal development;
recessive mutations on PASS2 cause the genetic disorder
spondyloepimetaphyseal dysplasia (SEMD), Pakistani type and
degenerative osteoarthritis [28]. Papss2
2/2 knockout mice have
shortened limbs, reduced axial skeletal length, and complex facial
features. Its transcripts were also present in the heart and brain in
mouse embryos [29].
Discussion
Cohesin consists of four major proteins SMC1A, SMC3, SCC1,
and SCC3. NIPBL plays a role in shuttling cohesin onto and off
the chromatin, although the exact mechanism of its action is
poorly understood. All proteins in this pathway are evolutionally
conserved from yeast to human [30]. Cell-cycle related sister
chromatid cohesion, DNA repair, and homologous rearrangement
are well established roles for the cohesin apparatus. A role for
cohesin in regulating gene expression has also been proposed and
appears to be more sensitive to subtle dosage alterations of the
cohesin apparatus and its regulators than its canonical function in
sister chromatid cohesion [31]. In both yeast and Xenopus, the
loading of cohesin onto chromatin in G1 phase is functionally
separable from the establishment of sister chromatid cohesion at S
phase [32,33]. In Drosophila, Nipped-B mediates interactions
between the promoter and remote enhancers for cut and
Ultrabithorax; heterozygous Nipped-B mutants diminish cut expres-
sion in the emergent wing margin without showing cohesion
defects indicating sister chromatid cohesion is independent from
cohesin regulated gene expression [34]. In mice, Pds5b mutants
have multiple CdLS-like defects without flawed sister chromatid
cohesion [35].
In humans, CdLS is caused by heterozygous loss-of-function
mutations in the NIPBL ortholog of Nipped-B and, in a smaller
percent of cases, by mutations in the SMC1A or SMC3 cohesin
subunit genes [17,18,36,37]. Given the constellation of develop-
mental abnormalities present in individuals with CdLS, with only
a subset showing minor cohesion defects [20,38], it is likely that
the alterations of cohesin regulation and structure seen in these
individuals result in gene expression dysregulation. We chose to
use an easily accessible but a seemingly developmentally irrelevant
tissue, LCLs, for these studies. We hypothesized that congenital
genetic disorders might arise, in part, through dysregulation of
expression of specific genes and that expression differences
between affected and unaffected individuals might be present in
tissues other than disease presenting tissues. These cells also
provide an invaluable resource of naturally occurring mutant
cohesin proteins (both structural and regulatory components of
cohesin) that can be used to study the cellular processes regulated
by this complex and specifically the impact on regulation of gene
expression. Surprisingly these cells may also provide valuable
insight into human developmental processes as well.
We have identified specific gene expression profiles for CdLS
that are capable of classifying probands and tightly correlate with
disease severity. Cohesin preferentially binds to promoter regions
of the actively expressed genes suggesting a role as a general
transcription factor. These binding sites are significantly reduced
in NIPBL mutant CdLS samples. This result is likely due to
NIPBL’s direct role in cohesin loading on chromatin, which in
turn affects transcriptional regulation at specific loci and would
contribute to the CdLS pathogenesis. Out of the 339 dysregulated
genes with FDR,0.01, 202 were upregulated (59.6%) and 137
were downregulated (40.4%), more genes were reactivated than
inhibited with mutations in NIPBL (59.6% versus 40.4%,
p=3.44e217) suggesting that NIPBL and cohesin can result in
both negative (as transcriptional repression) and positive (as
transcriptional activation) effects on expression. A similar percent-
Figure 5. Cohesin and CTCF colocalize and separate the active chromatin region from the repressive chromatin region. The cohesin
site at this position is lost in CdLS, thus the silencing epigenetic signal from region 3 is able to migrate into region 2, which harbors ATP11A and
downregulates its transcription. (A) Screen shot of ENCODE ENr132 region from the UCSC genome browser is displaying histone methylation and
acetylation status, CTCF binding sites, and DNaseI sensitivity sites on this region in GM06990 cells (from Sanger Institute and University of
Washington databases, respectively). hSCC1-Control and hSCC1-CdLS are custom tracks. hSCC1-Control track indicates the results of whole genome
cohesin binding analysis in LCLs from controls, whereas hSCC1-CdLS track indicates the results of whole genome cohesin binding analysis in LCLs
from the CdLS proband; data on CTCF_Bcell2_8 track are adapted from Wendt et al. [10]. (B) Schematic of ENr132 locus as in (A). Five genes located in
three regions are displayed. Two cohesin and six CTCF binding sites are shown. Cohesin and CTCF colocalize at Chromosome 13: 112,645,000–
112,645,600, which separates region 2 from region 3. Cohesin binding at this position was lost in CdLS proband. (C) ChIP-qPCR validation in three
different healthy controls ‘‘Normal,’’ ‘‘N6,’’ and ‘‘N12’’ and three additional CdLS probands ‘‘PT2,’’ ‘‘PT12,’’ and ‘‘CDL-017.’’ Cohesin bound to this locus
was dramatically reduced among CdLS probands including a proband with an SMC1A mutation (CDL-017). Sites 1 and 2 are positive controls, site 8
spans Chromosome 13: 112,645,000–112,645,600.
doi:10.1371/journal.pbio.1000119.g005
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among the 1,501 dysregulated genes with FDR,0.05. Moreover,
71 of the above 339 genes (20.9%) and 207 of the 1501 genes
(13.8%) have fold changes larger than 1.5, whereas the highest fold
changes are 24.2 and +4.6, respectively. Although the majority of
expression levels seemed only mildly perturbed, developmental
deficits in CdLS are likely due to a cumulative change in multiple
genes. Another reason for less remarkable expression differences
could be the LCL tissue type used for this study, with bigger fold
changes in more genes possibly present in more directly affected
tissues of, e.g., brain or limb, and at specific times during
embryonic development. However, it is also possible that the
transcriptional dysregulation may be directly mediated by NIPBL
through a yet uncharacterized mechanism and the reduced
cohesin binding may be a secondary effect. In our study, a 30%
reduction in NIPBL message was able to trigger a 29.7% (9,530
versus 13,560) reduction in cohesin binding sites in CdLS
probands and further affects the transcription of specific genes.
The central components for sister chromatid cohesion, RAD21
(SCC1), SMC1A, SMC3, STAG2, ESCO1, ESCO2, and PDS5A (also
known as SCC-112), are all expressed similarly between controls
and CdLS probands with NIPBL mutations. However, STAG1,
PDS5B (also known as APRIN), MAU2L (KIA0892), as well as
several other genes with functions related to sister chromatid
cohesion were significantly dysregulated in NIPBL mutant CdLS
probands (FDR,0.05) (Table S13), suggesting that the cohesin
pathway itself is affected by mutant NIPBL. MAU2 (KIAA0892) is
the putative human homolog of scc4 in Caenorhabditis elegans [31,39].
It forms an essential loading complex with NIPBL that regulates
cohesin-chromatin association, sister-chromatid pairing, and
mitotic checkpoints in HeLa cells. Physical association between
NIPBL and MAU2 is indispensable for their stability, as depletion
of either of the two proteins would subsequently diminish the
cellular level of the other one [39]. In our study, decreased NIBPL
transcription (21.33, FDR=0) was able to upregulate the
transcription of MAU-2 (+1.11, FDR=0.026), suggesting a
functional compensation may exist for cohesin loading in CdLS.
A cohesin-independent mechanism has also been suggested to
exist. Condensin complexes [40], origin recognition complexes
(ORCs) [41], centromere complexes [42], and DNA catenation
[43] have each been reported to play a role in mediating cohesin-
independent sister chromatid cohesion. Genes involved in these
functions are also found to have dysregulated expression in NIPBL
mutant individuals (Table S13). This finding indicates a subset of
genes regulated by NIPBL are tightly involved in sister
chromosome segregation events, but expression alteration may
be required to pass a certain threshold in order to induce visible
cohesion defects. This observation could explain why cell lines
derived from CdLS probands did not demonstrate significant sister
chromatid pairing problems. In contrast to CdLS, cohesion defects
have been reported in three human developmental disorders: RBS
(OMIM 268300) [19], Rothmund–Thomson syndrome (RTS,
OMIM 268400) [44], and a-Thalassemia/mental retardation
syndrome, X-linked (ATRX, OMIM 301040) [45]. Interestingly,
although the expression of the RBS disease causative gene ESCO2
was not dysregulated in CdLS cell lines, the other two disease
genes, ATRX and RECQL4, both demonstrated dysregulation in
NIPBL mutant cell lines (Table S13).
Several cohesin targets have been identified. Steroid hormone
ecdysone receptor (EcR), which is the Drosophila homolog of human
NR1H3, was suggested to be regulated by Smc1, and Runx3 was
identified as a direct target of Rad21 in zebrafish [46,47]. The fact
that both of these genes were also significantly dysregulated
(FDR,0.05) in CdLS probands with NIBPL mutations indicates
that NIPBL may first affect cohesin proteins and subsequently
dysregulate cohesin targets. Surprisingly, we did not find that
cohesin directly binds to these two genes in the cell line studied,
which raises the possibility that cohesin may regulate their
expression over long distances. When comparing ChIP-on-chip
results for Nipped-B and/or SMC1A binding sites in three
different Drosophila cell types [48], homologs of 20 differentially
expressed human genes in CdLS probands (FDR,0.05) were also
found to be bound by NIPBL and cohesin (unpublished data).
Eight of these 20 genes are also bound by cohesin in humans
suggesting they may be cohesin targets in both Drosophila and
humans. It also suggests that cohesin mediated transcription is a
conserved biological event. Moreover, most of the binding sites
were lost in CdLS cells indicating dysregulated gene expression
correlates with loss of cohesin binding. Among the eight genes,
KMO, ELL2, and ARHGAP17 have cohesin binding at TSSs;
ROBO1, UBE2H, MED13L, RASA3, and PDPK1 had cohesin
binding within intronic regions. One of these genes, ROBO1
(homolog of lea in Drosophila), is of particular interest as it was
found to have a fold change of 4.6, which is the largest among all
the genes on the array. ROBO1 has been associated with dyslexia,
a neurocognitive disorder of language and graphic processing that
could be due to the abnormal migration and maturation of
neurons during early development.
We have identified groups of 23, 10, and 3 genes as CdLS
classifiers or biomarkers that are capable of differentiating CdLS
from non-CdLS samples. The expression levels of these genes also
correlate to the phenotypic severity of this disorder, although it is
not clear at this time how the dysregulation of these particular
genes might contribute to the phenotypes. More than 60% of the
identifier genes harbor intragenic cohesin binding sites with some
of them lost in CdLS proband. The obvious overrepresentation of
genes carrying intragenic cohesin binding sites among the CdLS
classifier genes further suggests that expression of the dysregulated
genes is tightly related to the availability of cohesin binding.
Overall, the majority of genes do not carry known cohesin binding
sites, indicating that cohesin may play an upstream role in
regulating human genes, or cohesin may enact regulation on some
of the genes through distal cis-o rtrans-regulatory elements. The
potential role for cohesin independent NIPBL regulation can not
be excluded.
Cohesin has recently been found to be physically and
functionally associated with the vertebrate insulator protein
CTCF. In our study cohesin binds to only ,20% of genes
intragenically. This distribution does not change much between
expressed genes and silent genes, and between differentially
expressed genes in CdLS and disease neutral genes. Cohesin could
be involved in gene regulation, like CTCF, by either binding to
promoter elements and having a direct influence on the
transcriptional machinery or by binding to intergenic cis-elements
such as insulators to control gene expression from remote distances
[49]. In our study, we have detected a potential boundary effect of
cohesin at the ATP11A gene locus that suggests, for the first time in
humans, that cohesin may bind to insulators and regulate
transcription. Reduced cohesin binding at this locus was further
validated in three additional CdLS probands by the more sensitive
ChIP-qPCR including probands with either NIPBL mutations or
cohesin subunit SMC1A mutation. However, cohesin does not
exactly mimic the function of CTCF, at least in LCLs. Some
CTCF target genes, such as PIM-1 [50] and APP [51], although
expressed in LCLs, are neither dysregulated in CdLS nor do they
lose cohesin binding at their regulatory regions. On the other
hand, the CTCF target gene, BRCA1 [52], was downregulated in
CdLS (21.2, FDR=0.017) but without losing cohesin binding
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more genomic loci will delineate a clearer picture of cohesin and
CTCF effects on transcriptional regulation. The role cohesin plays
in imprinting and X inactivation remains unclear [53].
In summary, we have undertaken a genome-wide approach to
study gene expression and cohesin binding in NIPBL mutant
human samples. On the basis of our data and previously reported
studies, we propose that NIPBL may be involved in modulating
cohesin function through various mechanisms. Besides its
canonical role in regulating sister chromatid segregation proposed
by Haering et al. [54] (Figure 6A), cohesin may also regulate
transcription (1) as an insulator protein by acting alone or with
CTCF, or (2) as a transcription factor by binding to promoter
elements. While regulating transcription, NIPBL may also serve as
a cohesin shuttle to chromatin that leads to decreased cohesin
binding when NIPBL is mutated. Data from this study are quite
consistent with this role. Whether this loading mechanism either
partially overlaps with, or is completely independent from NIPBL-
mediated sister chromatid cohesion remains unknown (Figure 6B).
NIPBL and cohesin may very well form one protein complex
binding to regulatory elements of target genes, with NIPBL
mutations affecting the regulatory capacity of this complex
(Figure 6C). The colocalization of NIPBL and cohesin seen in
Drosophila studies could be consistent with this model [9]. A third
possibility is that NIPBL is able to maintain an accessible
chromatin structure for cohesin binding whereas defective NIPBL
leads to reduced accessibility for cohesin at specific chromosomal
loci (Figure 6D).
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of The Children’s Hospital of
Philadelphia and Misakaenosono Mutsumi Developmental, Med-
ical, and Welfare Center. All patients provided written informed
consent for the collection of samples and subsequent analysis.
Sample Collection
All participants were evaluated by one or more experienced
clinicians. Gene mutations were confirmed by sequencing, and
most of the cases have been previously reported by our
laboratories [17,55,56].
Cell Lines and Culture Condition
LCLs were grown uniformly in RPMI 1640 with 20% fetal
bovine serum (FBS), 100 U penicillin/ml, 100 mg streptomycin/
ml sulfate, and 1% L-glutamine. To identify differentially
expressed genes between CdLS probands and controls, age
and gender matched samples from 16 normal controls of
European descent and 17 clinically severely affected probands
of European descent with NIPBL protein-truncating mutations
(nonsense or frameshift) were chosen as the training set for the
discriminate analysis. To validate the expression pattern obtained
from the training set, six samples including one healthy control,
one Egyptian CdLS proband, two Roberts syndrome probands,
and two Alagille probands were used as the testing set. All 39
cell lines were grown anonymously and the processing of these
39 cell lines were randomized by genotypes to eliminate batch
effects that may contribute to genotype-specific gene expression.
Samples are listed in Table S1A and S1B with detailed
description. For custom array analysis, detailed information of
these samples is listed in Table S7. Out of these 101 samples of
European descent, the training set included 17 healthy controls
and 14 severely affected CdLS probands with NIPBL protein-
truncating mutations. All 31 samples were also used for the
training in Affymatrix array analysis. For the testing set, all new
samples were selected, which included four healthy controls, six
severely affected probands, 13 moderately affected probands
(nine have NIPBL mutations and four do not have an identifiable
mutation), and 34 mildly affected probands (26 have NIPBL
mutations and eight do not have an identifiable mutation). We
have also included nine CdLS probands with SMC1A mutations,
as well as four samples with different genetic diagnoses (two
AGS, one Roberts syndrome, and one unknown multisystem
genetic disorder). As above, samples were processed anonymous-
ly and randomly.
5610
6 exponentially growing cells were seeded in 15 ml media
in a 75-ml Falcon flask, and fed exactly after 24 h. After an
additional 24 h on day 3, 8 ml of the media was removed and cells
were pelleted by centrifuge and RNA extraction was performed
immediately.
RNA Isolation and Affymatrix Expression Array
Hybridization
Total RNA from each sample was extracted with the RNeasy
Mini-kit (Qiagen), synthesis of double-stranded cDNA was
performed using SuperScript Double-Stranded cDNA Synthesis
kit (Invitrogen), and cleaned up with GeneChip Sample Cleanup
module (Affymetrix). The resulting products were then used to
synthesize biotin-labeled cRNA with Enzo Bioarray High Yield
RNA Transcript Labeling kit (Enzo Life Sciences) and further
fragmented to 35–200-bp oligos. All procedures were done
according to manufacturer’s instructions. 30 ml fragmented cRNA
at the concentration of 500 ng/ml was sent for hybridization in the
microarray facility at The Children’s Hospital of Philadelphia.
Microarray hybridizations were performed by using HG-U133
plus 2.0 GeneChips (Affymetrix). The HG-U133 plus 2.0 contains
,54,000 25-mer probe sets that covers approximately 47,000
transcripts and variants out of which 38,500 are well-characterized
human genes. After hybridization and washes, arrays were
scanned and analyzed both for genes that were present and for
expression level using Microarray Analysis suite (MAS) 5.0 using
default settings according to manufacturer’s instructions.
Custom-Built Target Array Hybridization
The same RNA isolation process was performed as above. 32
genes were selected by clustering-based feature selection and 59
probes were designed (Table S8). Probe designing, RNA labeling,
and hybridization were conducted using the Ziplex workstation
(Xceed Molecular, http://www.xceedmolecular.com/). In brief,
concentrations of the isolated RNA were determined by measuring
the absorbance at 260 nm. All total RNA samples were of
acceptable purity (ratio of the absorbance at 260 nm to 280 nm of
1.75 or greater). The integrity of the total RNA was determined to
be acceptable for all samples (RNA Integrity Numbers measured
with the Agilent 2100 Bioanalyzer RNA 6000 Nano assay were
greater than 9.0). A custom Ziplex TipChip microarray containing
oligonucleotide probes of between 35 and 50 bp for 32 genes was
used to profile differences in gene expression between the LCL
samples. Total RNA (500 ng) from 108 independent samples was
amplified and biotin labeled with the Illumina Totalprep RNA
amplification kit (Ambion). The concentrations of the labeled
aRNAs were determined by measuring the absorbance at 260 nm,
and 3 mg was hybridized on the custom TipChip with the Ziplex
Automated Workstation protocol (Xceed Molecular). After
hybridization, the Ziplex Automated workstation software auto-
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PLoS Biology | www.plosbiology.org 12 May 2009 | Volume 7 | Issue 5 | e1000119Figure 6. Proposed working models for cohesin and NIPBL. (A) Cohesin’s canonical role in regulating sister chromatid cohesion with NIPBL
acting to facilitate the loading and unloading of the cohesin complex onto the chromosomes. It is not known if NIPBL directly interacts with
chromatin. This model was described by Haering et al. [54]. (B) Cohesin loading model: NIPBL loads cohesin onto chromatin at the promoters or cis-
regulatory elements after which cohesin regulates transcription without the direct involvement of NIPBL. (C) Cohesin and NIPBL collaborative model:
Cohesin and NIPBL form a protein complex that binds to promoters or cis-regulatory elements. The functional integrity of this complex is required for
transcriptional regulation of target genes. (D) NIPBL chromatin remodeling model: NIPBL may affect the accessibility for cohesin, e.g., by changing
chromatin structures, to bind to chromatin elements through yet unknown pathways. Transcriptional regulation through cohesin is secondarily
affected.
doi:10.1371/journal.pbio.1000119.g006
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subtracted expression values. The Ziplex software automatically
evaluated attributes of each spot to identify spots that did not
conform to quality control criteria and reported the mean value of
the duplicate spots of each probe that passed quality control.
ChIP Microarray Analysis
Two healthy controls and one severely affected CdLS proband
with an NIPBL protein-truncating mutation (G5483A) were used.
Cells were crosslinked with 1% formadehyde at 70%–80%
confluency for 10 min, chromatin was then prepared after
quenching with 125 mM glycine and ChIP was performed as
described [57] using anti-hRAD21 polyclonal antibodies (Abcam,
ab992). In brief, lysates from crosslinked cells were incubated with
the antibodies and preabsorbed protein A Affiprep beads (Bio-
Rad) for 14 h at 4uC and for 2 h at 4uC, respectively. After
washing, the beads were incubated in the elution buffer (50 mM
Tris, 10 mM EDTA, 1% SDS) for 20 min at 65uC. The elutes
were treated with proteinase K for 1 h at 37uC and followed by
65uC overnight incubation for crosslink reversal. The samples
were then treated with RNase and phenol-chloroform purified for
one time, and further purified using PCR purification kit (Qiagen)
with 80 ml water used for the final elution.
The eluted chromatin was amplified and labeled with biotin
then hybridized to high-density oligonucleotide tiling arrays
(Human tilling 2.0R array, Affymetrix) as described [58]. A
sample of DNA prepared from whole cell extract (WCE) was
prepared in the same way. ChIP and WCE samples were
hybridized on arrays according to the manufacturer’s instructions,
two technique replicates were used for each sample. After scanning
and data extraction, enrichment values (ChIP/WCE) were
calculated by using the MAT algorithm [59]. MAT is designed
for high-density oligonucleotide tiling-array analyses in higher
eukaryotes that could reduce probe-specificity biases because of
genome complexity or high GC content. The resulting MAT
scores are proportional to the logarithm transformed value of the
fold-enrichment of the ChIP-chip samples [59]. We mapped MAT
scores to positions in human genome assembly Hg 18 (NCBI Build
36). Bandwidth, MaxGap, and MinProbe parameters were set to
250, 1,000, and 12, respectively. The cutoff threshold of p-values
was set to 1610
26, which was equivalent to MAT scores higher
than 4.85. FDRs were also calculated with every experiment less
than 1% (Figure S4A and S4B). BED files were created, data were
visualized in the Integrated Genome Browser (IGB) (http://www.
affymetrix.com/support/developer/tools/download_igb.affx) and
University of California Santa Cruz (UCSC) genome browser
custom track (http://genome.ucsc.edu/).
ChIP-qPCR
ChIP was performed as described above using hRAD21 and
control antibodies. ChIP-qPCR analysis was performed as
previously described [10]. ChIP samples (2 ml) were used for one
25-ml PCR reaction. Analyses by qPCR were performed using a
Platinum SYBR Green qPCR SuperMix UDG (Invitrogen) on an
ABI 7500 cycler. The results were presented as fold-enrichment
over control ChIP.
Statistical Analysis
Gene expression microarray data were processed by DNA-Chip
Analyzer (dChip) (http://www.dchip.org) using PM-only back-
ground subtraction and invariant set normalization. Differential
gene expression between controls and CdLS probands was ranked
by the ratio of between- and within-group variance (F statistic).
During nearest centroid classification, distance of testing samples
to training group centroids was measured as their Pearson’s
correlation coefficient. Statistical analyses were performed within
R software environment (http://www.r-project.org). PCA and
heatmap plots were generated by Spotfire DecisionSite version
9.1.1 (Spotfire, Inc.). More details about data analysis are provided
in Text S1.
Accession Numbers
Genomic sequences reported in this manuscript have been
submitted to NCBI GEO (http://www.ncbi.nlm.nih.gov/geo):
gene expression data are under accession number GSE 12408 and
ChIP-chip data are under accession number GSE 12603.
Supporting Information
Figure S1 Expression level of three genes (NFATC2, PAPSS2,
and ZNP608) for controls and probands. (A) 17 healthy controls
and 14 severely affected CdLS probands with NIPBL protein
truncating mutations, and (B) 101-sample cohort used for target
array analysis including the same individuals as in (A). Three axes
represent expression of the three genes, blue dots represent
controls, including healthy participants and individuals with other
genetic diagnoses; red dots represent CdLS probands.
Found at: doi:10.1371/journal.pbio.1000119.s001 (0.26 MB PDF)
Figure S2 ChIP-qPCR validation of 13 cohesin binding sites
identified by ChIP array. RAD21 ChIP samples were obtained
from the CdLS proband and the control in the ChIP array studies
and were analyzed by qPCR for the presence of 13 different
cohesin binding sites with site-specific primers (mean of n=3; error
bars +/2 standard deviation [SD]) (see Table S11 for genomic
addresses of the 13 sites and primer sequences). The results were
presented as fold-enrichment over control ChIP (nonantibody). (A)
The presence of cohesin binding at 13 examined genomic sites,
sites 1 and 2 were bound equally by cohesin in both probands and
control in the array studies and served as positive controls here;
sites 3 and 4 did not demonstrate cohesin binding in either
proband or control in the array studies and served as negative
controls here; sites 5–13 are nine genomic sites where cohesin
binding was lost in the CdLS cells by qualitative analysis in the
array studies. Quantitative PCR has revealed the amount of
cohesin bound to these sites is significantly reduced at all of the
examined loci. (B) Quantitative analysis of average amount of
cohesin bound to the nine examined sites revealed at least half of
cohesin binding is lost in the CdLS cells.
Found at: doi:10.1371/journal.pbio.1000119.s002 (0.36 MB PDF)
Figure S3 Cohesin binding within +/2 100 bp around TSSs is
enriched in differentially expressed genes. The 10,378 unique
genes expressed in LCLs are ranked by their F scores. The
reference enrichment is the overall percentage of genes having
cohesin binding within 200 bp (+/2 100 bp) around TSSs. The
relative enrichment is calculated as the value of cohesin binding
enrichment in top-ranked genes over the reference enrichment.
The relative enrichment point is calculated for the total number of
genes prior to the point on the x-axis. The numbers on x-axis
denote the number of top-ranked genes. The curves are smoothed
by the LOWESS algorithm.
Found at: doi:10.1371/journal.pbio.1000119.s003 (0.23 MB PDF)
Figure S4 FDRs of genome-wide ChIP microarrays of (A)
controls and (B) CdLS proband. The x-axis denotes the p-values
and the y-axis denotes the average FDR percentage for each
experiment. Note that the FDR is less than 1% at the threshold
p-value=10
26 adopted for the analyses performed in this study.
Found at: doi:10.1371/journal.pbio.1000119.s004 (0.33 MB PDF)
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whole genome expression array analyses. (A) 16 LCL samples from
severely affected CdLS probands with identified protein-truncat-
ing mutations of NIPBL were used for the training set. (B) 17 LCL
samples from healthy controls were also included in the training
set for expression array analyses. An additional six samples were
used as a testing set.
Found at: doi:10.1371/journal.pbio.1000119.s005 (0.23 MB PDF)
Table S2 1,915 probe sets representing 1,501 unique genes
(FDR,0.05) are differentially expressed in CdLS.
Found at: doi:10.1371/journal.pbio.1000119.s006 (0.35 MB PDF)
Table S3 339 nonredundant genes represented by 420 probe
sets (FDR,0.01) are differentially expressed in CdLS.
Found at: doi:10.1371/journal.pbio.1000119.s007 (0.24 MB PDF)
Table S4 Evaluation of Leave-One-Out cross-validation for the
33 samples in the training set. Two healthy controls and one
proband were misclassified.
Found at: doi:10.1371/journal.pbio.1000119.s008 (0.22 MB PDF)
Table S5 Five functional independent gene clusters identified
among the 339 genes (FDR,0.01) using GSEA online program
and R code.
Found at: doi:10.1371/journal.pbio.1000119.s009 (0.24 MB PDF)
Table S6 32 genes chosen by clustering-based feature selection
for custom array analysis.
Found at: doi:10.1371/journal.pbio.1000119.s010 (0.23 MB PDF)
Table S7 Cohort of 101 individuals of European descent
selected for custom array validation. Clinical evaluation and gene
mutations of this cohort are listed.
Found at: doi:10.1371/journal.pbio.1000119.s011 (0.27 MB PDF)
Table S8 56 probes designed for the 32 selected genes for the
custom array.
Found at: doi:10.1371/journal.pbio.1000119.s012 (0.22 MB PDF)
Table S9 Step wise method to select the 23- and ten-gene
classifiers and the three-gene biomarkers.
Found at: doi:10.1371/journal.pbio.1000119.s013 (0.23 MB PDF)
Table S10 Intragenic cohesin binding in mapped human
RefSeq genes. The total number of mapped human RefSeq
transcripts is 15,162, whereas 4,784 genes are not transcribed in
LCLs (group A); 9,199 genes are transcribed but not differentially
expressed in CdLS (group B); and 1,179 genes are both
transcribed and differentially expressed in CdLS (group C). (A)
Cohesin binding is reduced in group A genes (18.9% of 4,784
genes) but increased in group C genes (27.0% of 1,179 genes) as
compared to all the mapped transcripts (22.0% of 15,162 genes).
Group B genes demonstrate little change (22.9% of 9,199 genes) as
compared to all mapped transcripts. In CdLS, the number of
genes bound by cohesin in all the groups is significantly reduced
(all transcripts, 22.0% R 16.0%; group A genes, 18.9% R 13.8%;
group B genes, 22.9% R 16.8%; group C genes, 27.0% R
18.5%). (B) In both control and CdLS, when compared to the
number of genes bound by cohesin in all the mapped transcripts
(22.0% in control and 16.0% in CdLS), group A has a significantly
reduced percentage of genes bound by cohesin (p#7.2e26i n
control and p#0.000187 in CdLS), whereas group C has a
significantly increased percentage of genes bound by cohesin
(p#7.44e25 in control and p#0.0249 in CdLS), and group B does
not demonstrate a statistically significant change in cohesin
binding (p#0.0864 in control and p#0.0836 in CdLS). *p,
binomial proportions comparing intragenic cohesin binding
between control and CdLS; **p, binomial proportions comparing
intragenic cohesin binding between individual group (A, B, or C)
and all the mapped transcripts.
Found at: doi:10.1371/journal.pbio.1000119.s014 (0.27 MB PDF)
Table S11 Specific primer pairs used for ChIP-qPCR valida-
tion. Primer pair 1 and 2 amplify regions that are bound by
cohesin equally in healthy and CdLS cells, and served here as
positive controls. Primer pair 3 and 4 amplify regions that are not
bound by cohesin in either healthy or CdLS cells, and served as
negative controls. Primer pair 5 to 13 amplify regions that were
identified as having lost cohesin binding in CdLS cells by the
qualitative ChIP array studies.
Found at: doi:10.1371/journal.pbio.1000119.s015 (0.22 MB PDF)
Table S12 Intragenic cohesin binding in the classifier genes and
the gene ontology analysis. The appearance of a cohesin binding
site is described as ‘‘+,’’ binding in both CdLS proband and
control cells is shown. The involvements of multiple bio-functions
and canonical pathways of each gene are also listed based on the
IPA analysis. The 10-gene classifier and the three biomarkers are
part of the 23-gene classifier.
Found at: doi:10.1371/journal.pbio.1000119.s016 (0.27 MB PDF)
Table S13 Dysregulated genes (FDR,0.05) identified in CdLS
probands with NIPBL mutations that are functionally related to
cohesion pathways. Genes that have FDR between 0.05 and 0.1
are highlighted in red.
Found at: doi:10.1371/journal.pbio.1000119.s017 (0.23 MB PDF)
Text S1 Supporting methods and statistical analysis.
Found at: doi:10.1371/journal.pbio.1000119.s018 (1.31 MB PDF)
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